Iomai Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Iomai is a biopharmaceutical company focused on the research and development of vaccines and immune system stimulants based on its TCI technology for the prevention and treatment of infectious diseases. Its proprietary technology, TCI, combines the safe use of powerful adjuvants and targets Langerhans cells in the skin which enhances the vaccine efficacy,thereby improving existing vaccines.

Report Highlights
Iomai's main product focus is the development of immunostimulant patches and needle-free vaccine patches for influenza and pandemic flu and to prevent E. coli-related travelers' diarrhea.

The company's lead product candidate, needle-free travelers' diarrhea vaccine patch, is undergoing Phase II trial for the treatment of travelers' diarrhea, caused by enterotoxigenic E. coli bacteria. Iomai's second candidate, IS patch for pandemic influenza, is in Phase I/II for the treatment of pandemic influenza.

The company's third product candidate, needle-free flu vaccine patch is undergoing Phase I trial for treatment of seasonal influenza. Iomai derives entire revenues from US federal grant programs which primarily includes grants from National Institutes of Health (NIH) to advance development of its IS patch technology for pandemic flu applications.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 7
Company Overview and Key Facts 7
Business Description 8
History 10
Company Financials 11
Stock Market Performance 11
P&L 12
Balance Sheet 15
Cash Flow 15
Products & Services 16
Pipeline Products 16
AC Forecast Product Sales 18
Competitors and Strategic Business Relationships 19
Top Competitors 19
Key Suppliers 20
Key Clients 20
Shareholding Structure 22
Strategy 23
Company View 23
Strategy 24
SWOT Analysis 26
Overview 26
Strengths 27
Weaknesses 28
Opportunities 29
Threats 30
Value Chain Analysis 31
Overview 31
Discovery and Product Development 32
Manufacturing 32
Scorecard 33
Overview 33
Scorecard Analysis 34
Key Employees 35
List of Key Employees 35
Key Employee Biographies 36
Financial and Operational Overview 43
Financial and Operational Overview 43
Appendix 45
Ask the analyst 45
Datamonitor consulting 45
Disclaimer 45
[Inhaltsverzeichnis ausblenden]

Table 1: Iomai - Key Facts 7
Table 2: Iomai - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
Table 3: Iomai - Key Events Impacting Share Price Performance 11
Table 4: Iomai - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Table 5: Iomai - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
Table 6: Iomai - Balance Sheet, 2002-2006 ($ Mn) 15
Table 7: Iomai - Cash Flow, 2002-2006 ($ Mn) 15
Table 8: Iomai – In-house Pipeline Products 16
Table 9: Iomai – Forecast Sales, 2006-2010 ($ Mn) 18
Table 10: Iomai – Top Competitors 20
Table 11: Iomai – Key Suppliers 20
Table 12: Iomai – Key Clients 21
Table 13: Iomai - Key Shareholders 22
Table 14: Iomai - SWOT Analysis Summary 26
Table 15: Iomai – Value Chain Analysis 31
Table 16: Iomai - Scorecard 33
Table 17: Iomai - Key Employees 35
Table 18: Iomai - Financial and Operational Overview 43
Figure 1: Iomai - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
[Tabellenverzeichnis ausblenden]